• Scalable EPSC-iMSC EV Platforms: Therapeutic and Manufacturi

  2026-05-22

  This study introduces a standardized, scalable platform for producing extracellular vesicles (EVs) from extended pluripotent stem cell-derived mesenchymal stem cells (EPSC-iMSCs) using bioreactor systems. The resulting EVs exhibit robust therapeutic efficacy in preclinical fibrosis models and address key bottlenecks in clinical translation, including donor variability and manufacturing scalability.

• Applied Use of SB 202190 as a p38 MAP Kinase Inhibitor in Re

  2026-05-22

  SB 202190 delivers precise, reversible p38 MAP kinase inhibition for dissecting MAPK signal transduction in inflammation, cancer, and neuroprotection. Explore stepwise protocols, troubleshooting advice, and novel insights from both canonical and emerging experimental models.

• Tigecycline: Next-Gen Glycylcycline for Advanced Resistance

  2026-05-21

  Explore Tigecycline's unique role as a first-in-class glycylcycline antibiotic, with a deep dive into its application in advanced multidrug-resistant bacteria models. This article reveals practical assay implications, recent gene transmission insights, and workflow advantages for researchers.

• Tunicamycin as a Precision Lever in Translational ER Stress

  2026-05-21

  This thought-leadership article outlines how Tunicamycin, a potent N-glycosylation inhibitor from APExBIO, uniquely enables mechanistic dissection of ER stress and inflammation in translational models. Integrating recent evidence from trauma-immune research and advanced application strategies, it guides researchers beyond standard protocols toward strategic, reproducible, and clinically relevant insights.

• Practical Guide to Omeprazole for Gastric Acid Secretion Res

  2026-05-20

  Omeprazole (SKU A2845) is a potent H+,K+-ATPase inhibitor used to investigate gastric acid secretion mechanisms and antiulcer drug activity. This compound should be applied strictly within research settings focused on proton pump inhibition and peptic ulcer disease models, and is not suitable for diagnostic or medical use.

• Cinoxacin in Gram-Negative Infection Research: Protocols & P

  2026-05-20

  Cinoxacin, a potent quinolone antibiotic, is pivotal in modeling Gram-negative infections and antibiotic resistance. This guide translates core bench workflows, protocol refinements, and troubleshooting solutions for researchers leveraging Cinoxacin in urinary tract infection and resistance studies.

• ERAD-Engaging Chimeras Enable Targeted Degradation of TM Pro

  2026-05-19

  Song et al. report the development of ERAD-engaging chimeras (ERADECs), a novel small-molecule technology that selectively induces degradation of transmembrane proteins by hijacking the endoplasmic reticulum-associated degradation pathway. This approach overcomes a major barrier in targeted protein degradation, offering new strategies for modulating membrane protein function in disease research.

• Doxycycline: Tetracycline Antibiotic & Metalloproteinase Inh

  2026-05-19

  Doxycycline is a tetracycline antibiotic widely used for its broad-spectrum antimicrobial and metalloproteinase inhibitory properties. Its applications extend to cancer research, where it exhibits antiproliferative activity against cancer cells and serves as a valuable tool for studying disease pathways.

• Lenalidomide (CC-5013) in Myeloma: Protocols, Synergies, and

  2026-05-18

  Lenalidomide (CC-5013) stands at the forefront of immunomodulatory research in multiple myeloma, offering potent immune activation and anti-angiogenic effects. This guide translates cutting-edge findings—such as the synergy with DOT1L inhibition—into actionable protocols and troubleshooting tips, empowering bench scientists to drive translational breakthroughs.

• Oral Faropenem Sodium: AMR Risks and Efficacy Insights

  2026-05-18

  This article analyzes recent findings on oral Faropenem sodium, focusing on its broad-spectrum antimicrobial activity, oral bioavailability, and the emerging risks of antimicrobial resistance (AMR). The discussed evidence highlights the clinical and societal implications of increasing faropenem use and cross-resistance within the penem antibiotic class.

• Faropenem Sodium (SKU C8712): Reliable Penem Antibiotic Solu

  2026-05-17

  This article details how Faropenem sodium (SKU C8712) from APExBIO addresses key challenges in cell viability and bacterial inhibition workflows. By examining real lab scenarios, it demonstrates evidence-backed advantages in reproducibility, compatibility, and protocol optimization for advanced antimicrobial and resistance studies.

• Doxycycline: Tetracycline Antibiotic for Mechanotransduction

  2026-05-16

  Doxycycline’s dual role as a tetracycline antibiotic and metalloproteinase inhibitor enables cutting-edge research in both antimicrobial and cancer biology. This overview details advanced workflows, protocol optimization, and troubleshooting strategies for maximizing Doxycycline’s impact in 3D cell culture and mechanotransduction assays.

• Cefotaxime in AMR Research: Precision, Plasmid Dynamics, and

  2026-05-15

  Explore how Cefotaxime, a third-generation cephalosporin antibiotic, advances antimicrobial resistance research by enabling high-fidelity modeling of plasmid-mediated resistance and experimental reproducibility. Discover new insights on transmission dynamics and practical assay considerations not covered by prior literature.

• IPA-3: Selective Pak1 Inhibition for Advanced Kinase Assays

  2026-05-15

  IPA-3, a selective non-ATP-competitive Pak1 inhibitor, empowers researchers to dissect kinase signaling with unmatched specificity—enabling high-fidelity kinase activity assays and translational research in cancer and neuroregeneration. This article decodes stepwise protocols, troubleshooting strategies, and practical insights, uniquely leveraging APExBIO's IPA-3 for robust experimental outcomes.

• OMV-Based mRNA Antigen Display Enables Rapid Personalized Tu

  2026-05-14

  This study introduces a novel platform using bacteria-derived outer membrane vesicles (OMVs), engineered to rapidly display and deliver mRNA antigens for personalized cancer vaccination. By leveraging OMV surface proteins and endosomal escape mechanisms, the approach offers a distinct and efficient alternative to lipid nanoparticle-based mRNA delivery, showing significant tumor regression and immune memory in preclinical models.

16701 records 1/1114 page Next 12345 下5页 Last page